Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Simple Summary A significant number of patients diagnosed with non-small cell lung cancer
(NSCLC) will have a metastatic Stage IV disease at presentation. Among those, patients with …

Simple Summary Synchronous oligometastatic non-small cell lung cancer (NSCLC)
represents an intermediate state of metastatic disease with a limited number of metastases …

Background Local treatment (LT) such as radiotherapy and metastasectomy on metastatic
sites may improve outcomes in oligometastatic NSCLC patients, but more data are …

The standard first-line treatment for non-oncogene driven metastatic non-small cell lung
cancer (NSCLC) is an immune checkpoint inhibitor (ICI) based strategy. Although guidelines …

Every year, the European Respiratory Society (ERS) offers grants to recognise the best
overall abstracts of the 14 ERS Assemblies submitted for the ERS International Congress …

Oligometastatic non-small cell lung cancer (NSCLC) is an intermediate state between
localized and widely metastatic NSCLC, where systemic therapy in combination with …

Résumé Le concept de maladie oligométastatique suggère que les patients atteints d'un
nombre limité de métastases de pronostic favorable. Le traitement local radical des cancers …

Introduction The role of local ablative treatments, including stereotactic body radiotherapy
(SBRT), is an area of active research in oligometastatic patients. Small cell lung cancer …